NEW

FDA Updates Information on Respirator Decontamination Systems

The U.S. Food and Drug Administration (FDA) is reissuing the Emergency Use Authorizations for decontamination systems that are authorized to decontaminate compatible N95 respirators for use by healthcare personnel (HCP) to prevent exposure to pathogenic biological...

First Patient Treated in Clinical Trial of BCL System

CairnSurgical, Inc., an innovator striving to make breast cancer surgery more precise, announced that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital.

Rush Oak Park Hospital Adopts Surgical Workflow Technology, ExplORer Surgical, Increasing Team Confidence and Reducing OR Challenges

ExplORer Surgical, the only comprehensive intraoperative case support and workflow platform, has reinvented the way surgical support teams prepare and complete effective surgeries with two-way video for case support and remote proctoring to create a digitized playbook.

AORN Releases 2021 Guidelines for Perioperative Practice

The Association of periOperative Registered Nurses (AORN) has published the 2021 Guidelines for Perioperative Practice with six revised guidelines.

KARL STORZ Receives Innovative Technology Designation for Blue Light Cystoscopy

KARL STORZ Endoscopy-America Inc.’s system for performing Blue Light Cystoscopy with Cysview (BLCC) has received an Innovative Technology designation from Vizient Inc., the largest member-driven health care performance improvement company in the country.

The designation was based on reviews of BLCC by hospital experts who attended Vizient’s Innovative Technology Exchange during September 2016. The event provided medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from 1,300 onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to an organization’s care and business model.

The BLCC system uses the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system in conjunction with Cysview, an optical imaging agent distributed in the U.S. by Photocure, Inc. The combined system is used to enhance the detection and management of Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with known or suspected bladder cancer, based on prior cystoscopy. Use of the technology begins with placement of Cysview into the bladder prior to the procedure, where it accumulates in tumor cells and is converted into porphyrins within the tumor. When viewed with the D-Light C PDD system, the tumor cells appear red or pink in contrast with normal cells, which appear blue in color. The system is capable of delivering both conventional white light to illuminate the bladder during routine cystoscopy, as well as a special blue light to induce and view fluorescence after the placement of Cysview.

“Use of the KARL STORZ D-Light C PDD system for BLCC procedures gives vital new capabilities to physicians,” says John Martineau, Director of Marketing Urology, KARL STORZ. “Used as an adjunct to white-light cystoscopy, BLCC is the only FDA-approved technology that is shown to improve detection of bladder cancer tumors hence leading to improved and more comprehensive tumor resection.”

KARL STORZ Endoscopy-America, Inc., was previously recognized by Vizient, Inc. and also awarded the Innovative Technology designation in 2015 for its IMAGE1 Visualization Enhancement System.

Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X